NASH Drug Candidate Comes With 'Serious Risks,' Says FDA Staff Agency reviewers signal little support for first potential nonalcoholic steatohepatitis drug May 17, 2023
Statins Linked to Slower Liver Disease Progression Risk 40% lower with use among those with preexisting liver disease, study found May 04, 2023
Bariatric-Metabolic Surgery More Effective Than Lifestyle Change for NASH Roux-en-Y bypass or sleeve gastrectomy resolved NASH without exacerbating liver fibrosis Apr 26, 2023
Transplant Chief Was an Organ Recipient Herself Years ago, she had a liver transplant. Now she leads Hopkins' pediatric liver transplant program Apr 19, 2023
NKF Roundup: Latest Data on Tolvaptan, Terlipressin, and Lumasiran More research from the National Kidney Foundation Spring Clinical Meeting Apr 17, 2023
Adjuvant Combo May Change Practice in High-Risk Liver Cancer Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
Another Measure of Terlipressin Success in Hepatorenal Syndrome Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal Apr 13, 2023
Smaller Liver Transplant Candidates Wait Longer, Less Likely to Receive Organ Disparity mostly affects women, but allocating more livers from smaller donors may help Mar 29, 2023
FDA Mandate on Acetaminophen-Opioid Combinations Appeared Effective Hospitalizations for liver toxicity declined after FDA limited acetaminophen dose Mar 07, 2023
Avoiding Just This Dietary Trigger Helps Resolve Eosinophilic Esophagitis Easier alternative to six-food elimination diet shown effective Mar 01, 2023
'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancer No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab Jan 22, 2023
Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
Direct-Acting Antivirals Linked to Improved Outcomes in Chronic Hepatitis C All-cause mortality rate significantly lower in treated versus untreated group Dec 13, 2022
Abstinence Tied to Lower Mortality in Alcoholic Cirrhosis With Portal Hypertension Benefit observed even in patients with high-risk portal hypertension Dec 08, 2022
Robotic Surgery Proves Its Mettle for Liver Cancer Fewer cases of liver failure, similar survival versus open liver resection in matched analysis Nov 23, 2022
Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA? Latest REGENERATE analysis comes on heels of REVERSE flop Nov 11, 2022
Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitis Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH Nov 11, 2022
Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon Nov 10, 2022
Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH Nov 10, 2022
Maralixibat Takes Out the Itch of Rare Liver Disease Ileal bile acid transporter inhibitor could become second drug for PFIC Nov 09, 2022
Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndrome Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder Nov 09, 2022
Acamprosate Appears Safe for People With AUD and Liver Disease Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients Nov 09, 2022
BP Control Beneficial for Liver Transplant Recipients Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year Nov 07, 2022
Earlier Terlipressin May Be Better for HRS-AKI in Acute-on-Chronic Liver Failure More acute kidney injury reversals at 7 days and lower mortality with initiation at 12 hours Nov 07, 2022
Pandemic's Impact on Liver Disease in the Spotlight at Liver Meeting A roundup of news from the AASLD annual meeting Nov 04, 2022
New HRS Drug Cuts Need for Renal Replacement Tx After Liver Transplant Follow-up data from CONFIRM trial show terlipressin benefit in key subgroup Oct 25, 2022
New Standard-of-Care Therapy for Advanced Liver Cancer Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone Oct 24, 2022
FDA Approves New CTLA-4 Inhibitor for Cancer Treatment Tremelimumab (Imjudo), in combination with durvalumab, lands approval in advanced liver cancer Oct 24, 2022
Bariatric Surgery in NAFLD Tied to Lower Heart Disease Risk In a large cohort, surgery associated with 49% lower risk of CVD versus nonsurgical care Oct 07, 2022
Noninvasive Gastric Mapping; Best Foods for the Gut? Lab Score for Crohn's News and commentary from the world of gastroenterology and hepatology Sep 22, 2022
Obeticholic Acid Tied to Better Outcomes in Primary Biliary Cholangitis Study comparing randomized trial with two external cohorts showed fewer deaths, transplants Sep 22, 2022
FDA Finally OKs First Drug for Hepatorenal Syndrome Pivotal trial data showed terlipressin nearly doubled reversal of the condition Sep 15, 2022
Ryan Reynolds' Colonoscopy; NASH Drug Passes Phase II Test; New Drug Target in IBD? News and commentary from the world of gastroenterology and hepatology Sep 14, 2022
More GI Docs, Fewer Alcoholic Liver Disease Deaths Study suggests access might account for 40% of alcohol-associated liver disease deaths nationally Aug 08, 2022
Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone Aug 04, 2022
Rare Mutations Linked to Protection Against Liver Disease Carriers of CIDEB variants were at lower risk for liver disease of any cause, study shows Jul 27, 2022
Novel Antifibrotic Improved Fibrosis in Chronic Hepatitis B Phase II trial from China suggests benefit of add-on therapy Jul 15, 2022
Unexplained Acute Hepatitis in Children: More Evidence for Adenovirus 41 Two studies point to a suspiciously high prevalence Jul 13, 2022
Odevixibat Scratches the Itch of Kids' Rare Liver Disease Phase III trial showed reduced pruritus in progressive familial intrahepatic cholestasis Jul 08, 2022
Hep C Cure Aside, Some Patients Still Benefit From Liver Cancer Screening Hepatocellular carcinoma risk persisted after direct-acting antivirals Jun 30, 2022
